US2020031939A1PendingUtilityA1

Antibodies Against Human NKG2D and Uses Thereof

Assignee: NOVO NORDISK ASPriority: Dec 14, 2007Filed: Oct 17, 2019Published: Jan 30, 2020

Est. expiryDec 14, 2027(~1.4 yrs left)· nominal 20-yr term from priority

Inventors:Birgitte Urso Peter Andreas Nicolai Reumert Wagtmann Inger Lund Pedersen Anders Svensson

A61P 37/00A61P 37/02A61P 37/06A61P 29/00A61P 25/00A61P 3/00A61P 1/00A61P 21/00A61P 19/02A61P 1/04A61P 17/00A61P 17/06C07K 2317/76C07K 2317/55C07K 16/2851C07K 2317/34C07K 2317/565C07K 2317/92C07K 2317/24C07K 2317/56C07K 2317/74C07K 2317/21C07K 2299/00

PatentIndex Score

Cited by

References

Claims

Abstract

As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.

Claims

exact text as granted — not AI-modified

1 . A method of treating an inflammatory disease or disorder with an isolated antibody or an antigen-binding fragment thereof which binds human NKG2D (hNKG2D) and comprises
 (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO:48;   (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO:49;   (c) a heavy-chain variable region CDR3 comprising the sequence of SEQ ID NO:50;   (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO:51;   (e) a light-chain variable region CDR2 comprising the sequence of SEQ ID NO:52; and   (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO:53.   
     
     
         2 . A method of treating an autoimmune disease or disorder with an isolated antibody or an antigen-binding fragment thereof which binds human NKG2D (hNKG2D) and comprises
 (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO:48;   (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO:49;   (c) a heavy-chain variable region CDR3 comprising the sequence of SEQ ID NO:50;   (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO:51;   (e) a light-chain variable region CDR2 comprising the sequence of SEQ ID NO:52; and   (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO:53.   
     
     
         3 . A method of producing an isolated antibody or an antigen-binding fragment thereof which binds human NKG2D (hNKG2D) and comprises
 (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO:48;   (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO:49;   (c) a heavy-chain variable region CDR3 comprising the sequence of SEQ ID NO:50;   (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO:51;   (e) a light-chain variable region CDR2 comprising the sequence of SEQ ID NO:52; and   (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO:53, comprising culturing a host cell comprising a nucleic acid encoding the antibody or antigen binding fragment under suitable conditions and recovering said antibody or antigen binding fragment thereof.

Join the waitlist — get patent alerts

Track US2020031939A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.